RIMA HALL: Open Payments
NPI 1073195475 · DEARBORN, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$481 in 26 payments from 11 companies in 2025. Trend: 2023 $412 · 2024 $745 · 2025 $481
Food & beverage: $481
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $142 |
| AstraZeneca Pharmaceuticals LP | 5 | $80 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| ABBVIE INC. | 2 | $45 |
| PFIZER INC. | 2 | $42 |
| Novo Nordisk Inc | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| GlaxoSmithKline, LLC. | 1 | $18 |
| Abbott Laboratories | 1 | $16 |
| Indivior Inc. | 1 | $15 |
Products named: CAPLYTA, Auvelity, VRAYLAR, Ozempic, VOQUEZNA, PAXLOVID, AIRSUPRA, TRELEGY ELLIPTA.
Industry payments across MI — which companies pay providers there.
